Neumora Therapeutics Inc (NASDAQ: NMRA) on Tuesday, soared 6.82% from the previous trading day, before settling in for the closing price of $0.66. Within the past 52 weeks, NMRA’s price has moved between $0.62 and $17.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 4.37%. With a float of $64.36 million, this company’s outstanding shares have now reached $161.71 million.
Let’s look at the performance matrix of the company that is accounted for 110 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc is 60.21%, while institutional ownership is 37.39%. The most recent insider transaction that took place on Mar 12 ’25, was worth 21,450. Before that another transaction happened on Feb 18 ’25, when Company’s insider sold 13,871 for $1.69, making the entire transaction worth $23,468. This insider now owns 7,405,004 shares in total.
Neumora Therapeutics Inc (NMRA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.37% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 10.51 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Neumora Therapeutics Inc (NASDAQ: NMRA) saw its 5-day average volume 1.04 million, a negative change from its year-to-date volume of 2.87 million. As of the previous 9 days, the stock’s Stochastic %D was 26.67%. Additionally, its Average True Range was 0.09.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 0.77%, which indicates a significant decrease from 23.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.98% in the past 14 days, which was lower than the 274.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2224, while its 200-day Moving Average is $7.9892. Nevertheless, the first resistance level for the watch stands at $0.7289 in the near term. At $0.7529, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.7847. If the price goes on to break the first support level at $0.6731, it is likely to go to the next support level at $0.6413. The third support level lies at $0.6173 if the price breaches the second support level.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 114.03 million based on 161,748K outstanding shares. Right now, sales total 0 K and income totals -243,790 K. The company made 0 K in profit during its latest quarter, and -58,820 K in sales during its previous quarter.
